Fig. 2From: Platelet-rich plasma inhibits Adriamycin-induced inflammation via blocking the NF-κB pathway in articular chondrocytesPRP inhibits doxorubicin-induced chondrocyte apoptosis. ATDC5 cells and primary articular chondrocytes were treated with elevated concentrations of PRP and 40 doxorubicin for 24 h. A, B CCK-8 assay to determine ATDC5 viability after PRP (A) or doxorubicin (B) treatment. C Western blot assay to detect protein levels of PARP and cleaved PARP in ATDC5 cells. D, E CCK-8 assay to determine the viability of primary articular chondrocyte cells treated with PRP (D) or doxorubicin (E). F Western blot assay to detect protein levels of PARP and cleaved PARP in primary articular chondrocyte cells. At least three independent experiments were performed. *p < 0.05 vs controlBack to article page